Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Innovestor Life Science Fund is an active Finnish venture capital fund investing in early-stage biotech and digital health startups across the Nordics and Baltics. Its €90 million fund has backed at least 12–13 disruptive life science companies since 2022, including university spinouts developing novel therapies for neurological diseases and women’s health. Portfolio highlights include investments in Polku Therapeutics (neurodegeneration), Neumirna Therapeutics (RNA therapies for neurological disorders), and Gesynta Pharma (non-hormonal endometriosis treatment). The fund typically co-invests with international partners and supports preclinical through Phase II development[1][3][4][5].
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Innovestor.